E-scape's expansion

The opportunity to take up a second asset that will expand E-Scape Bio Inc.'s pipeline and diversify its clinical risk led the company to bring two new investors on board and extend its series A round, increasing the target to $63 million.

Apart from a June SEC filing related to the extension, the company had been keeping itself under wraps. It formally announced the extension and new investors July 12...